Duodenocutaneous fistula in rats as a model for "wound healing-therapy" in ulcer healing: the effect of pentadecapeptide BPC 157, L-nitro-arginine methyl ester and L-arginine.
Skorjanec. S S; Kokot. A A; Drmic. D D; Radic. B B; Sever. M M; Klicek. R R; Kolenc. D D; Zenko. A A; Lovric Bencic. M M; Belosic Halle. Z Z; Situm. A A; Zivanovic Posilovic. G G; Masnec. S S; Suran. J J; Aralica. G G; Seiwerth. S S; Sikiric. P P
Key Findings
- BPC‑157 (10 µg/kg or 10 ng/kg) fully healed duodenal fistulas in rats, eliminated leakage, restored sphincter pressure, and reduced mortality to 0 %.
- The nitric‑oxide synthase inhibitor L‑NAME worsened the fistula and increased death, while the NO precursor L‑arginine improved outcomes but more slowly.
- BPC‑157 neutralized the negative effects of L‑NAME and worked synergistically with L‑arginine, suggesting a strong link to the nitric‑oxide system.
Practical Outcomes
- For biohackers, this study hints that BPC‑157 could be a powerful oral or injectable aid for gastrointestinal ulcer or wound healing, likely acting through nitric‑oxide pathways. While the data are from rats, the low microgram‑per‑kg doses used suggest that human oral dosing (e.g., 250‑500 µg daily) might be effective. However, human trials are still needed, so start cautiously and monitor gut health if experimenting.
Summary
In rats with a serious gut wound (a duodenocutaneous fistula), the peptide BPC‑157 dramatically healed the damage, stopped leaks, restored stomach valve function, and prevented death. It worked whether given by injection or in drinking water, and even over‑rode the harmful effects of a nitric‑oxide blocker. Arginine (a nitric‑oxide precursor) also helped, but not as fast as BPC‑157.
Abstract
While very rarely reported, duodenocutanenous fistula research might alter the duodenal ulcer disease background and therapy. Our research focused on rat duodenocutaneous fistulas, therapy, stable gastric pentadecapeptide BPC 157, an anti-ulcer peptide that healed other fistulas, nitric oxide synthase-substrate L-arginine, and nitric oxide synthase-inhibitor L-nitro-arginine methyl ester (L-NAME). The hypothesis was, duodenal ulcer-healing, like the skin ulcer, using the successful BPC 157, with nitric oxide-system involvement, the "wound healing-therapy", to heal the duodenal ulcer, the fistula-model that recently highlighted gastric and skin ulcer healing. Pressure in the lower esophageal and pyloric sphincters was simultaneously assessed. Duodenocutaneous fistula-rats received BPC 157 (10 μg/kg or 10 ng/kg, intraperitoneally or perorally (in drinking water)), L-NAME (5 mg/kg intraperitoneally), L-arginine (100 mg/kg intraperitoneally) alone and/or together, throughout 21 days. Duodenocutaneous fistula-rats maintained persistent defects, continuous fistula leakage, sphincter failure, mortality rate at 40% until the 4(th) day, all fully counteracted in all BPC 157-rats. The BPC 157-rats experienced rapidly improved complete presentation (maximal volume instilled already at 7(th) day). L-NAME further aggravated the duodenocutaneous fistula-course (mortality at 70% until the 4(th) day); L-arginine was beneficial (no mortality; however, maximal volume instilled not before 21(st) day). L-NAME-worsening was counteracted to the control level with the L-arginine effect, and vice versa, while BPC 157 annulled the L-NAME effects (L-NAME + L-arginine; L-NAME + BPC 157; L-NAME + L-arginine + BPC 157 brought below the level of the control). It is likely that duodenocutaneous fistulas, duodenal/skin defect simultaneous healing, reinstated sphincter function, are a new nitric oxide-system related phenomenon. In conclusion, resolving the duodenocutanenous fistulashealing, nitric oxide-system involvement, should illustrate further wound healing therapy to heal duodenal ulcers.
Study Information
pubmed
2015